The heart is exquisitely sensitive to mechanical stimuli to adapt rapidly to physiological demands. In muscle lacking dystrophin, such as Duchenne muscular dystrophy, increased load during contraction triggers pathological responses thought to worsen the disease. The relevant mechanotransducers and therapies to target them remain unclear.
T he working heart rapidly adjusts to changes in mechanical load to adapt to physiological demand. A primary example is the augmentation of contractility that ensues when a heart is subjected to higher afterload as occurs with increased systemic resistance. This stress-stimulated contractility (SSC) response, often termed the Anrep effect, 1,2 allows the heart to provide similar cardiac output, despite higher load. The mechanisms are thought to involve mechano-stimulated proteins that ultimately result in a rise of intracellular calcium [Ca] 2+ i . Candidates for these transducers revealed in passively stretched noncontracting cells include stretch-activated G-protein-coupled receptors such as the angiotensin type 1 receptor, 3 members of the transient receptor potential (TRP) superfamily of cation channels, [4] [5] [6] [7] and the recently described piezo (1 and 2) proteins. 8 The SSC response, however, involves stress imposed during contraction, and here data identifying the relevant transducers remain scant. Understanding this signaling may be particularly important to disorders such as Duchenne muscular dystrophy (DMD), in which a lack of the cytoskeletal protein dystrophin results in pathologically augmented responses to systolic load, which are thought to be a core mechanism for progressive muscle disease.
Insight into this signaling pathway may be gleaned from studies of more sustained pressure overload that identified both TRP canonical (TRPC) 3 and TRPC6 channels as modulators of the pathological cardiac response. [9] [10] [11] TRPC6 is also a putative mechanosensitive channel in noncontracting cells, 6, 7 although this remains somewhat controversial. 12 Another feature shared by TRPC3 and TRPC6 is their post-translational modification by the serine/threonine kinase, protein kinase G (PKG) at analogous residues in their intracellular N terminus (T11 and S263 for TRPC3, T70 and S322 for TRPC6, human gene). [13] [14] [15] [16] [17] This modification reduces channel conductance in vitro and, for TRPC6, has been shown to suppress activation of a calcineurin/nuclear factor of activated T-cells (NFAT) signaling pathway and its associated hypertrophy. 14, 16, 17 Whether PKG modification of these channels also affects mechanosensing is unknown. Intriguingly, strategies to stimulate PKG are currently being studied in experimental [18] [19] [20] [21] and human dystrophinopathy 22 spawned initially by its potential effect on vasomotor function in skeletal muscle, 18, 22 and some early evidence supports cardiac benefits. 20, 21 Accordingly, the present study tested the role of TRPC3 and TRPC6 in the modulation of systolic mechanosensing in cardiac muscle and intact myocytes and whether their influence is regulated by PKG. Second, we tested whether this pathway is altered in experimental cardiac muscular dystrophy and if so, whether it is ameliorated by acute and chronic PKG activation. We reveal PKG to be a potent negative modulator of the SSC via a TRPC6-dependent mechanism. Furthermore, we show that TRPC6 mechanosignaling is excessive in dystrophin-deficient muscle and cells leading to abnormal calcium entry, excess force, and arrhythmia. All of these are blocked by targeted TRPC6 suppression and by acute or chronic PKG activation.
Methods
An expanded Methods section is available in the online-only Data Supplement. All studies were conducted in accordance with National Institutes of Health Guidelines for the Care and Use of Animals and reviewed by the Institutional Animal Care and Use Committee at Johns Hopkins University, where the work was performed.
Animals
TRPC3 knockout (KO; Trpc3 −/− ) and TRPC6 KO (Trpc6 −/− ) mice were generated as previously described. 23, 24 Each TRPC KO mouse was backcrossed for ≥5 generations into a C57BL6/J background, and their cross yielded the combined TRPC3/TRPC6 double KO (Trpc3 −/− /6 −/− ) mouse. Heterozygous mice were crossed to yield KO and littermate controls. Both KO models displayed selectivity for the TRPC channel involved, preserving normal levels of expression for other TRPC channels (Online Figure I) . For all studies, age-matched gene −/− and gene +/+ littermate controls at 4 to 6 months of age were used. For a model of DMD, female mice lacking dystrophin (mdx, Jackson Laboratories) were crossed with mice with a heterozygous deletion of utrophin (utrn, Jackson Laboratories) and studies performed in either mdx/utrn +/− at 4±1 months of age or in a few instances, mdx/utrn −/− animals at 6 to 10 weeks of age because of their early mortality. Male mdx/utrn +/− were crossed with female Trpc6 −/− to generate male utrn +/− /Trpc6 +/− and female mdx +/− /utrn +/− /Trpc6 +/− , and their cross yielded male mdx/utrn +/− /Trpc6 −/− . Studies were performed at 4±1 months of age. Only male mice were studied, with some controls provided by male C57BL6/J mice as well.
Pharmaceuticals
A new selective dual TRPC3/TRPC6 small molecule inhibitor GSK2833503A (GSK503A, also denoted as example 19) 25, 26 was provided by GlaxoSmithKline Pharmaceuticals. GSK503A has an IC 50 =21 nmol/L for TRPC3 and 3 nmol/L for TRPC6. Corresponding IC 50 for volgate-gated calcium (Cav1.2) and sodium (Nav1.5), hERG, and TRP vanilloid TRPV1 and TRPV4) channels are 10000, 3300, >50 000, 6300, and 12 500, respectively. Cell permeable cGMP analog (8-pCPT-cGMP) and cAMP analog (8-Br-cAMP) were obtained from Sigma, and purified sildenafil from Pfizer. For in vivo studies, sildenafil citrate (Revatio, Pfizer) was compressed into soft rodent chow (Transgenic Dough Diet, Bio-Serv) and provided at a dose of 200 mg/kg per day for 2 months as described previously. 27 This dose yields a free plasma concentration in the range of 30 to 50 nmol/L, well within the selective range for phosphodiesterase (PDE) 5A.
Papillary Muscle Studies
Papillary muscle studies were performed as previously described. 28 Briefly, hearts were rapidly excised and placed in modified Krebs-Henseleit solution containing 30 mmol/L 2,3-butadione monoxime. The Krebs-Henseleit solution contained (in mmol/L) 141 NaCl, 50 dextrose, 25 NaHCO 3 , 5 HEPES, 5 KCl, 1.2 NaH 2 PO 4 , 1 MgSO 4 , and 2.0 CaCl, pH adjusted to 7.35, and bubbled with 95% O 2 and 5% CO 2 . Thin papillary muscle strips with chordae tendineae were dissected from the right ventricle. The muscle was connected to a force transducer (Scientific Instruments GmbH, Heidelberg, Germany) at one end and mechanical anchor at the chorda tendinae end, allowing the muscle to contract auxotonically. Calcium was measured by Fura-2AM (340 nm and 380 nm excitation, 510 nm emission). Fluorescence was collected by photomultiplier tube (R1527, Hamamatsu, Japan) with background recorded before dye loading. Fura-2AM (50 μg) was dissolved in 25 μL dimethyl sulfoxide and 25 μL Pluronic to which 2.755 mL Krebs-Henseleit, 4.3 mg/L tetrakis-(2-pyridylmethyl)ethylenediamine, and 5.0 mg/L cremophor were added. Muscles were loaded with this solution for 30 minutes. The muscle length (L max ) generating maximal developed force (max-min force; ΔF) was determined and then length reduced to 92% of this value.
On achieving steady state developed force (ΔF 0 ), muscles were stretched to 98% L max , and force and Ca 2+ were recorded for 10 minutes to assess the SSC. Figure 1 displays a schematic for the SSC response and its analysis. Developed force rose immediately on stretch (ΔF 1 , Frank-Starling Mechanism [FSM]) and was indexed by ΔF 1 −ΔF 0 . The subsequent more gradual rise in developed force (ΔF 2 −ΔF 1 ) assessed SSC.
Isolated Cardiac Myocyte Studies
SSC analysis was also performed in isolated loaded cardiac myocytes. Cell isolation was performed as described (online-only Data Supplement Methods). 28 Myocytes were incubated for 15 minutes with 1 µmol/L indo1-AM (Invitrogen, Molecular Probes, Carlsbad, CA) in Tyrodes (1.0 mmol/L Ca 2+ ). 29 Rod-shaped quiescent single cardiomyocytes were selected, and a pair of carbon or glass fibers (6 µm at one end, 20 µm at the other) coated with a biological adhesive (MyoTak) 30 was attached to both ends using micromanipulators. The thin fiber was compliant and its position digitally controlled by a piezoelectric translator (Physik Instrumente, P-841-80), whereas the other fiber was rigid and served as a mechanical anchor. Cells were electrically stimulated at 0.15 to 0.2 Hz with 15-ms pulses. Cardiomyocyte sarcomere length and fiber tip displacements were recorded at 120 Hz and analyzed in real time using IonOptix (MA) equipment and software. Cells were then stretched to increase sarcomere length by ≈4%, and active and passive force (F) was determined from fiber bending moment given by F=K(ΔL P −ΔL F ), where K is the effective fiber stiffness; ΔL F , the change in distance between the 2 fibers; and ΔL P , the displacement of piezoelectric translator. Components of the SSC were determined as for papillary muscle data.
Acute Transaortic Constriction In Vivo Studies
Adult Trpc6 −/− or littermate control mice were anesthetized with 3% isoflurane, the chest opened between ribs 2 to 4, and a 26-G needle placed on the transverse aorta. A micro pressure-volume catheter (Millar Instruments, TX) was inserted through a left ventricular apical stab and positioned so that the distal tip lay in the proximal aortic root. 31 Instantaneous pressure-volume loops were recorded using custom-developed hardware and software (WinPVAN). After obtaining rest data, the aorta was constricted with a 6.0 suture around the aorta and 26-G needle to increase ventricular afterload. Pressure-volume data were recorded during the initial 15 minutes after aortic banding. 
Statistical Analysis

Results
cGMP/PKG Activation Markedly Suppresses SSC
To test whether PKG modifies systolic mechanotransduction in heart muscle, SSC was first measured in isolated cardiac papillary muscles with or without incubation with membrane permeable cGMP. On exposure to 6% auxotonic stretch, Figure 1 . Stress-stimulated contractility (SSC). Immediately after papillary muscle or cardiomyocyte auxotonic stretch, there is rapid calcium-independent rise in developed force (ΔF 1 −ΔF 0 , Frank-Starling Mechanism [FSM]) followed by a more gradual rise that is associated with an intracellular calcium increase (ΔF 2 −ΔF 1 ). The latter is termed SSC, calculated by the augmentation in developed force after the acute FSM change. muscles exhibited an immediate rise in developed force reflecting length-dependent activation (FSM) followed by a gradual 20% to 30% rise in contractility (SSC) accompanied by high peak [Ca] 2+ i transients that occurred during the ensuing 10 minutes ( Figure 2A ). The FSM was unaltered, whereas the SSC response was markedly suppressed by preincubation with 8-pCPT-cGMP (1.0 mmol/L; Figure 2B and 2C).
Cyclic GMP-PKG can also target vascular cells and fibroblasts potentially influencing the muscle response; therefore, we tested whether its regulation of the SSC was myocyte autonomous. Isolated myocytes were attached to carbon or glass microfibers, and the same protocol was performed. With a rise in auxotonic stress, we again observed an immediate rise in developed force (FSM) followed by SSC ( Figure 2D ). Incubation with cGMP (0.1 mmol/L) did not alter the FSM but markedly depressed the SSC ( Figure 2E ). When myocytes were pretreated with the PKG inhibitor DT3 (0.2 µmol/L), the SSC response (both force and Ca 2+ ) was normal, despite subsequent exposure to cGMP ( Figure 2F ; summary data Figure 2G ). This was confirmed using an alternative PKG inhibitor Rp-8-CPT-cGMP (10 µmol/L; Online Figure II ). Thus, Ca 2+ -associated SSC induced by systolic stress is cardiac myocyte autonomous and can be potently suppressed by cGMP-PKG modulation.
SSC Modulation by cGMP Requires TRPC6 and Is Independent of TRPC3
To test the role of TRPC channels to the SSC and its suppression by PKG, papillary muscles from mice genetically lacking either Trpc3 −/− or Trpc6 −/− and respective littermate controls were studied. Cardiac muscle lacking Trpc3 exhibited behavior identical to controls ( Figure 3A ), whereas Trpc6 −/− muscle had a significantly blunted force and Ca 2+ SSC response ( Figure 3B ). The rapid FSM response was similar in all groups (Online Figure III) . In Trpc3 −/− muscle, incubation with 8-pCPT-cGMP also still profoundly inhibited the SSC as in littermate controls ( Figure 3C ; summary data Figure 3E ). However, in Trpc6 −/− mice, the SSC response remained unaltered despite cGMP incubation ( Figure 3D ), whereas littermate controls displayed marked suppression ( Figure 3F ). Thus, TRPC6, not TRPC3, contributes to the SSC response and is required for its suppression by PKG.
Because vascular cells and fibroblasts also express TRPC6, we again tested its role in isolated cardiomyocytes. Controls showed a robust SSC response that was cGMP inhibited, whereas Trpc6 −/− cells displayed a blunted SSC with no change in the response after cGMP incubation ( Figure 4A ). As an alternative to gene deletion, we also tested the role of TRPC6 with a new selective small molecule TRPC3/6 blocker (GSK503A, 5 µmol/L). 26 Given that the SSC was unaltered by TRPC3 gene deletion, GSK503A effects were interpreted as dependent on TRPC6. GSK503A depressed the SSC by ≈30%, similar to results from Trpc6 −/− cells ( Figure 4B ). As a negative control, we tested GSK503A in cardiac myocytes lacking both Trpc3 and Trpc6 and found no SSC effect, supporting its selectivity ( Figure 4B ).
Last, we tested the relevance of TRPC6 mechanosensing in the intact heart. Hearts in situ were subjected to 15 minutes of increased afterload induced by proximal aortic constriction and pressure-volume loops recorded ( Figure 4C ). In both groups, the rise in afterload was first manifest by loops rapidly becoming taller and narrower and shifting rightward (shown by the response after 1 minute). In controls, the loops then gradually shifted leftward, reflecting increased contractility countering the persistently high afterload. However, this latter response was reduced in Trpc6 −/− hearts. Mean data for maximal rate of pressure rise (dP/dt max ) and relaxation time constant (τ) are shown in Figure 4D . Controls with a rise in contractility and little delay in relaxation after high afterload contrasted to Trpc6 −/− mice that displayed a fall in contractility and delayed relaxation. Taken together, these results indicate that TRPC6 is an important mechanotransducer in cardiomyocytes and in vivo heart and is required for the modulation of cGMP-PKG suppression of afterload SSC.
Hyperactive SSC and Arrhythmia in Myocytes Lacking Dystrophin/Utrophin Are Related to TRPC6 and Suppressed by PKG Activation
We next asked whether TRPC6-dependent systolic mechanostimulation was abnormal in cells lacking dystrophin and utrophin (mdx/utrn +/− ) and whether this too could be modulated by PKG activation. The combined mutation model was used because the absence of dystrophin alone produces a mild phenotype in mice, in part, caused by compensatory upregulation of utrophin. Mice fully lacking both genes display a severe skeletal and cardiac pathology with early mortality (6-8 weeks), 32 whereas partial utrophin deletion still leads to earlier and more prominent heart disease (Online Figure IV) but can be more easily studied. In mdx/utrn +/− (and mdx/utrn −/− ) cells, the SSC force and corresponding [Ca] 2+ i transient increase were markedly amplified compared with controls ( Figure 5A ). Stressed cells frequently displayed arrhythmia minutes after load was increased, in some instances leading to cell demise. This exacerbated SSC response in myocytes from the DMDmodel heart was fully blocked by preincubation with cGMP ( Figure 5B and 5C ). In MD cells, gene expression for Trpc6 was elevated ≈3fold compared with controls ( Figure 6A ), whereas expression of Trpc1 and Trpc3 was unchanged. Poor signal/noise and antibody specificity combined with low expression levels precluded detection of protein by immunoblot; however, evidence for a functional role of TRPC6 was obtained by incubating DMD cells with GSK503A. This reversed amplified force and Ca 2+ SSC responses to control levels ( Figure 6B) . Figure 6C summarizes the effect of cGMP or GSK503A incubation on stress-induced arrhythmia. In DMD cells, arrhythmia prevalence was 6× higher than control but was restored to normal by cGMP or the TRPC3/6 blocker. The effect of cGMP was opposite to that from cAMP (8-Br-cAMP, 0.1 mmol/L), which increased stress-stimulated arrhythmia incidence in control and DMD cells, the latter approaching ≈80% of cells studied. This highlights the selective effect of cGMP-PKG as a negative modulator of this signaling.
To more directly test if TRPC6 was required for abnormal SSC responses in DMD myocytes, we crossed mdx/ utrn +/− with Trpc6 −/− mice and subjected isolated myocytes from the triple-mutant hearts (mdx/utrn +/− /Trpc6 −/− ) to the cell stress protocol. The SSC force and [Ca] 2+ i transient responses in these cells behaved like healthy controls ( Figure 6D ). Furthermore, cGMP exposure had no effect on the SSC in these cells. Collectively, these results strongly support a major role of TRPC6 to abnormal mechanostimulation in cardiac dystrophinopathy and its importance to the amelioration of this pathophysiology by cGMP-PKG stimulation.
Acute and Chronic Treatment of Dystrophic Myocytes and Hearts by PDE5A Inhibition Blocks Hyperactive SSC and Arrhythmia
Activation of PKG can be pharmacologically achieved in vivo by stimulating cGMP synthesis (nitrates or natriuretic peptides) or by blocking its hydrolysis by PDEs such as PDE5A. The latter is more amenable to chronic therapy (eg, sildenafil [SIL]) and has been shown to improve skeletal muscle fatigue 18 and blunt progressive cardiac dysfunction in mdx mice. 20 Incubation of normal cells with SIL alone (1 µmol/L for 10 minutes) did not alter the SSC ( Figure 7A ). However, the efficacy of PDE5A inhibition is itself dependent on how much cGMP is present, and resting isolated cells have low levels. We, therefore, next identified a low cGMP dose (1/10th that used previously, eg, 0.01 mmol/L) that had no effect itself on the SSC ( Figure 7B) ; however, when combined with SIL, the SSC was suppressed ( Figure 7C ; summary data Figure 7G ). In mdx/utrn +/− , SIL alone was effective ( Figure 7D ), potentially because of higher basal PDE5A activity in the model (3.5±0.5-fold compared with controls; P<0.001; Figure 8E ). Combining SIL with lowdose cGMP further suppressed the SSC (Figure 7F and 7G) .
To test if chronic PDE5A inhibition also ameliorated abnormal myocyte mechanoresponses in DMD, mdx/utrn +/− mice were treated for 2 months with SIL (200 mg/kg per day PO). This therapy blunted progressive chamber hypertrophy ( Figure 8A and 8B) and reduced myocyte cross-sectional area ( Figure 8C ). Cardiac function (fractional shortening) also declined slightly in the placebo group but was maintained in SIL-treated mice (Online Figure V) . Fetal gene markers of pathological hypertrophy (Nppa) and Trpc6 gene expression were elevated in DMD myocardium and were significantly reduced with SIL treatment ( Figure 8D ). Changes in Trpc6 were associated with modest directionally similar changes in calcineurin protein expression, although regulator of calcineurin-1 gene expression was similar in all groups (Online Figure  VI) . DMD mice displayed ≈4-fold higher myocardial PDE5A activity compared with controls and this declined with SIL treatment accompanied by a modest rise in PKG activity ( Figure 8E ). By contrast, PDE1 activity was similar to controls and unaltered by SIL ( Figure 8E) . Figure 8F displays the effects of chronic SIL treatment on cellular mechanostimulation, the primary focus of this study. SIL-treated cells displayed an essentially normal SSC response compared with those receiving placebo. When further incubated with GSK503A, the SSC response was unaltered in cells from SIL-treated DMD hearts. This is consistent with the notion that chronic SIL therapy had already reversed TRPC6 hyperactivity.
Discussion
This investigation reveals TRPC6 as a modulator of systolic load-induced contractility increases in cardiomyocytes, muscle, and intact hearts and that it is also required for PKGmediated suppression of this mechanical response. The normally adaptive mechanism is pathologically amplified in heart muscle lacking dystrophin/utrophin, resulting in dysregulated force and [Ca] 2+ i and arrhythmogenicity. Hyperactive mechanosensing in DMD is suppressed greatly by inhibiting or genetically deleting TRPC6 or by activating the cGMP/PKG pathway so long as TRPC6 is present. These results provide new insight into normal stress-induced contractility adaptations and reveal a novel therapeutic target for the dystrophic heart.
The SSC (or Anrep) response has been recognized for more than a century, yet its mechanisms have remained uncertain. Some attribute it to stretch-activated Gq protein-coupled receptors (GqPCRs, eg, angiotensin-II and endothelin-1) which via reactive oxygen species 33 generation induce extracellular signal-regulated kinase 1/2 activation of the Na +/ H + exchanger 1. The latter in turn results in higher [Ca] 2+ i via reverse mode Na + /Ca 2+ exchange. 2 Other studies support activation of stretch-activated channels 34 that themselves conduct Na + and Ca 2+ , with [Ca] 2+ i being further enhanced by the Na + /Ca 2+ exchange, Na +/ H + exchanger 1, or Ca 2+ released from internal stores. 35 The current results help reconcile these mechanisms by placing TRPC6 as an important upstream mechanosensor. TRPC6 is stimulated by GqPCRs, and in other cell types, can also activate extracellular signal-regulated kinase 1/2 36, 37 upstream of Na +/ H + exchanger 1 2 and conduct Na + that in turn triggers Ca 2+ entry via the Na + /Ca 2+ exchange. [38] [39] [40] The mechanosensing capacity of TRPC6 was first revealed by Spassova et al 7 in studies of smooth muscle cells exposed to osmotic or direct membrane passive stretch. TRPC6 mechanosensing was later reported in quiescent adult cardiac myocytes subjected to plasma membrane shear stress. 6 Some, however, have questioned this role and attributed earlier data to stretchactivated GqPCRs and artifacts from TRPC6 overexpression in heterologous systems. 12 The present data combine results from physiologically loaded myocytes, muscle, and intact hearts and use gene deletion and selective TRPC3/6 blockade to support the role of TRPC6 as a mechanosensor in both the normal heart and particularly hearts lacking dystrophin. The experiments did not involve artificial overexpression models, and although more proximal GqPCR stretch activation could still play a role, gene deletion and targeted pharmacological blockade studies strongly implicate TRPC6 as a critical node in the stress response.
Modulation of TRPC channel function by PKG was first reported for TRPC3 in human embryonic kidney 293 cells 13 and later in TRPC6 in similar cells 15 and cardiac myocytes. 14, 16 For TRPC6, this modification not only reduced cation conductance but also blunted associated signaling via calcineurin/NFAT activation triggered by Gq-coupled agonists. 14, 16 Phosphosilenced or phosphomimetic TRPC6 mutants display gain or loss of channel function, respectively, with respect to conductance and associated NFAT signaling. 14, 16 The current data add mechanosignaling to the list of TRPC6-mediated responses modified by cGMP/PKG, and this influence seems Figure 5A ). G, Summary results for these experiments (n=6-11/group, *P<0.01 vs +low-dose cGMP, #P<0.05 vs +low-dose cGM+SIL by ANCOVA). Low-dose cGMP had no effect itself on the SSC (nontreated control data shown by gray dashed lines) but when combined with SIL suppressed the SSC. SIL alone was effective in DMD cells. February 28, 2014 separable from effects on hypertrophic signaling. First, we identified its role in normal cells exposed to rapid stress that is unlikely to involve hypertrophic cascades. Second, we found that TRPC6 modulation of the SSC was greatly amplified in DMD, despite only modest evidence of calcineurin/NFAT activation in the same hearts. Last, TRPC3 was uninvolved with mechanoactivation or PKG modulation of SSC, yet it has been previously linked to calcineurin/NFAT activation and hypertrophy in chronic pressure-overloaded hearts. 10, 11, 41 Abnormal mechanoresponses in DMD skeletal muscle 42, 43 have long been considered fundamental to the disease. Stretch imposed on contracting DMD muscle induces enhanced [Ca] 2+ i and a decline in tetanic force, and these abnormalities are reduced by lowering Ca 2+ in the bathing solution or by blocking stretch-activated channels. TRPC1 has been proposed as a relevant stretch-activated channel, 44, 45 although TRPC6 is also expressed and may be involved. 46 The current study focusing on the heart reveals a key role of TRPC6 to altered mechanosensing. Afterload imposed on the heart during systole has a parallel with stretch imposed during skeletal muscle contraction. The consequential amplified rise in [Ca] 2+ i is thought to stimulate myocardial damage. This rise has been linked to plasma membrane defects 47, 48 and altered sarcoplasmic reticulum calcium handling, 49, 50 and the current study adds TRPC6 hyperactivity to this list.
The current results counter the notion that DMD myocytes are subject to stress-induced membrane tears that nonselectively leak cations because SSC force/Ca 2+ responses were both normalized by selectively blocking TRPC6 or activating PKG. However, membrane instability stemming because of a lack of dystrophin could well trigger TRPC6 hyperactivity, and surfactants 48 that can stabilize the plasma membrane may also suppress such hyperactivity. Interestingly, muscle cell permeability of Evans Blue in mdx declines from treatment with a stretch-activated channel inhibitor (streptomycin) 43 or with chronic SIL therapy. 21 Benefits in DMD skeletal muscle from PKG activation have been reported, with most data showing improved vascular perfusion. 18, 21, 22 Although some benefit has also been observed in the heart, 20 mechanisms have remained unclear. While longterm studies remain to be performed, the present data support that a PKG-TRPC6 targeting mechanism is likely involved. The findings that SSC was near fully blocked by cGMP/PKG so long as Trpc6 was expressed yet more modest suppression was observed when TRPC6 was inhibited or genetically deleted suggest that phosphorylated TRPC6 may interact and impair other proteins as well. This would be consistent with the observation that TRPC channels often form heterotetramers. The specific nature of such interactions remains to be elucidated.
There are several limitations of the current study. First, we were unable to measure TRPC6 phosphorylation by PKG directly in adult myocardium or isolated myocytes so as to relate this modification with the physiological behavior. As noted, this was because of low expression levels of the channel (even with enhanced gene expression) and poor antibody signals for both total Figure 8 . Amplified mechanoresponse in dystrophinopathy is blunted by chronic phosphodiesterase (PDE) 5A inhibition. A, Progressive cardiac hypertrophy (serial echocardiography) in Duchenne muscular dystrophy (DMD) mice was blunted by sildenafil (SIL) treatment (n=14-17/group, *P<0.05 vs placebo by ANCOVA), and these data confirmed by heart weight/body weight (HW/BW) at terminal study (B; n=5-8/group, *P<0.05 vs placebo). C, Myocyte cross-sectional area by wheat germ agglutinin staining, representative images, and summary data, scale bar, 50 µm; n=4 mice/group (>1000 cells/mouse), *P<0.05 vs control (Ctrl), #P<0.05 vs placebo. D, mRNA expression of A-type natriuretic peptide (Nppa) and Trpc6 (n=3-8/group, *P<0.05 vs Ctrl, #P<0.05 vs placebo). E, PDE5, PDE1, and protein kinase G (PKG) activity for each group (n=5/group, *P<0.01 vs Ctrl, #P<0.01 vs placebo). F, Amplified stress-stimulated contractility in mdx/utrn +/− is normalized after chronic SIL treatment and unaltered further by the addition of GSK503A (n=6-12/group, *P<0.05 vs placebo). and particularly phospho-TRPC6 from these tissues. Indeed, published data stem almost exclusively from human embryonic kidney 293 cells overexpressing the protein. 17 Nonetheless, such data confirm a strong influence of PKG-phosphorylation on the channel, suppressing GqPCRs or DAG-stimulated conductance and hypertrophy signaling. 14, 16, 17 The failure of PKG to modulate the SSC response in control or DMD myocytes without Trpc6 strongly supports this interaction. The chronic SIL study also supports targeting because cells from PKG-treated DMD hearts displayed no further effect from TRPC3/6 blockade. Another limitation resides with the new small molecule TRPC3/6 inhibitor that could not be tested in vivo, even for acute studies, because of high plasma binding and extremely rapid metabolism. 26 This compound has no known influence on TRPC6 phosphorylation and suppressed GqPCR-signaling in cells expressing a TRPC6 phosphomimetic (Trpc6 T70E,S322E ), indicating independence from this modification.
In conclusion, we identify TRPC6 as a cardiac systolic mechanosensor, primary target of PKG modulation of SSC, and a major contributor to mechanostimulation pathology in the DMD heart. Combined, Duchenne and Becker muscle diseases involving the absence or deficiency of dystrophin account for 80% of all muscular dystrophies. Although the major focus of prior research has been on often catastrophic skeletal muscle disease, the heart is potently involved as well, and heart failure is now a major cause of mortality. 51 The present results identify a novel and important role of TRPC6 and its modulation by PKG that may provide a new therapeutic avenue for these diseases.
